PainReform Ltd.
PRFX
$-0.84
Change (1 day)
$80.64
Year High
$1.73
Year Low
Categories
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd. (PRFX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 45 K | -7,950,000 | 2.69 M | 9.93 M | 9.8 M |
| 2022 | 55 K | -4,096,000 | 1.31 M | 12.33 M | 12.28 M |
| 2021 | 218 K | -16,537,000 | 991 K | 19.07 M | 19.02 M |
| 2020 | 53 K | -15,677,000 | 1.18 M | 17.8 M | 17.79 M |
| 2019 | 22 K | 5.23 M | 6.79 M | 1.16 M | 972 K |